Citigroup
LTRN icon

Citigroup’s Lantern Pharma LTRN Stock Holding History

Citigroup’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$62 Buy
+45
New +$126 ﹤0.01% 5631

Other funds holding LTRN

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citigroup's LTRN Position: Q1 2026 in Review

Citigroup opened a new position in Lantern Pharma (LTRN) in Q1 2026: 45 shares worth $62. The stake represents ﹤0.01% of the portfolio and ranks #5631 among its holdings.

33 funds tracked by Wall St. Rank hold LTRN as of Q1 2026.

  • Citigroup held 45 shares of Lantern Pharma worth $62 as of Q1 2026.
  • Lantern Pharma was a new Citigroup position in Q1 2026.
  • Lantern Pharma made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5631 holding.
  • 33 funds tracked by Wall St. Rank held Lantern Pharma as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.